Image For Activity Cover
Rise of Methamphetamine: New Risks, Current Treatments
Richard A. Rawson, PhD, Research Professor, Vermont Center for Behavior and Health, Professor Emeritus, UCLA Department of Psychiatry and Biobehavioral Sciences
Target Audience
This activity is designed to meet the needs of primary care physicians, specialty care physicians, allied professional staff and program administrators.
Webinar Description
Methamphetamine use has grown increasingly prevalent over the past couple decades, and fentanyl-contaminated methamphetamine has led to a significant increase in overdose deaths. Though no FDA-approved medications exist yet to treat methamphetamine use disorder, new research has demonstrated efficacy of various behavioral treatments, particularly contingency management. This webinar will provide an overview of the current state of methamphetamine use, considerations for concurrent opioid use, and strategies and interventions for treating and engaging individuals with stimulant use disorder.
Educational Objectives

At the conclusion of this activity, learners should be able to:

  • Examine trends in and impacts of methamphetamine use, including concurrent use with opioids
  • Identify clinical challenges and strategies for treating individuals who use stimulants
  • Examine the evidence for medications and treatment interventions for stimulant use
Availability: On-Demand
Expires on 10/28/2023
Cost: FREE
Credit Offered:
1 Attendance Credit
The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.

Funding for this initiative was made possible (in part) by grant nos. 6H79TI081968 and 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

For Buprenorphine Training Inquiries, email PCSS.


Powered By